More specifically, a statistically significant difference was observed in CD4+ T-cells being less frequent in patients with hematologic cancer compared to those who suffer from solid malignancies, whereas CD8+ T-cells were equally detected among those groups [142]. This evidence concerns the gene CD4 and hematopoietic and lymphoid cell neoplasm.